论文部分内容阅读
在用病毒唑(Ribavirin)治疗肾综合征出血热(Hemorrhagic fever with renal syndrome,HFRS)(以安慰剂作对照)的双盲法临床试验中,用微量酶联免疫吸附技术对确诊的64例患者血清和尿液中特异性IgG及IgM抗体水平进行动态观察与分析,结果发现,病毒唑治疗组两种血清抗体水平均较安慰剂对照组低(IgG,P<0.001;IgM,P<0.05),而两组患者尿液中两种抗体水平与阳性率均无明显差异,表明病毒唑对HFRS患者抗体的生成具有抑制作作用,本文就该作用的原因与后果进行了分析评价。
In a double-blind clinical trial of Ribavirin for Hemorrhagic Fever with Renal Syndrome (HFRS), a placebo-controlled trial, 64 patients with confirmed disease were analyzed by micro-enzyme-linked immunosorbent assay Serum and urine specific IgG and IgM antibody levels were observed and analyzed. The results showed that both serum antibody levels of ribavirin-treated group were lower than those of placebo control group (IgG, P <0.001; IgM, P <0.05) , While there was no significant difference between the two antibody levels and the positive rate in the two groups of patients, indicating that ribavirin has an inhibitory effect on the antibody production in HFRS patients. The causes and consequences of this effect were analyzed and evaluated.